Hinge Health, Inc.

NYSE:HNGE

Medical - Healthcare Information Services

Healthcare
$114.53 -0.36%

-$0.24 today

Market cap
$9.31B
Beta
1.99
P/E (TTM)
-10.3
EPS (TTM)
-$6.49
52W Low $30.08High $70.72

Volume 1.23M

Average 1.34M

HNGE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Hinge Health, Inc.NYSE: HNGE

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $34.06M fell 87.8% year over year, behind the -63.1% change in trailing-twelve-month research & development. Sequentially, it rose 12.3% from the prior quarter.

Context

  • Research & development amounted to 62.6% of revenue in FY2025, up 36.8 pp from a year earlier.
  • Research & development increased in 1 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly growth recovers from -87.8% toward the trailing-twelve-month pace of -63.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$34.06M+12.3% QoQ
Last fiscal yearDec 2025
$368.14M+265.1% YoY
LTMJun 2026
$129.07M-63.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-87.8%——
1 year+265.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
368.14M USD
Year-over-year change
+265.1%
2-year CAGR
+82.9%

Research & Development vs competitors

How HNGE compares with its peers on the latest reported figures

  • HNGE's LTM Jun 2026 research & development of $129.07M is the 2nd highest of the 5 companies compared; the peer median is $77.97M.
  • Its year-over-year change of -63.1% is the lowest of 4, against a peer median of +0.9%.
  • Research & development amounts to 17.9% of revenue for HNGE, versus a peer median of 5.5%.
HNGE Competitors Peer median
Research & Development for HNGE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNNSmith & Nephew plcFY2025$346M +0.9%+0.1%5.6%
HNGEHinge Health, Inc.LTM Jun 2026$129.07M -63.1%—17.9%
ENOVEnovis CorporationLTM Apr 2026$123.34M +27.9%+25.5%5.4%
OMDAOmada HealthLTM Mar 2026$32.6M -8.9%+15.8%11.5%
USPHU.S. Physical Therapy, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding HNGE) $77.97M+0.9%+15.8%5.5%

Competitors are the stored peer set for HNGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue292.73M390.4M587.86M
Cost of Revenue98.55M89.81M118.56M
Gross Profit194.18M300.59M469.3M
Gross Margin66.3%77.0%79.8%
Research & Development110.06M100.84M368.14M
Selling, General & Admin214.64M227.54M639.41M
Operating Expenses324.69M332.5M1.02B
Depreciation & Amortization5.63M5.95M5.13M
EBITDA(124.89M)(18.48M)(535.89M)
EBITDA Margin-42.7%-4.7%-91.2%
Operating Income(130.51M)(31.91M)(546.37M)
Operating Margin-44.6%-8.2%-92.9%
Interest Income000
Interest Expense000
Other Income / Expenses21.97M20.65M19.11M
Income Before Tax(108.55M)(11.26M)(527.26M)
Pre-Tax Margin-37.1%-2.9%-89.7%
Income Tax Expense(405K)677K998K
Net Income(108.14M)(11.93M)(528.26M)
Net Margin-36.9%-3.1%-89.9%
EPS (Basic)(1.39)(0.15)(5.36)
EPS (Diluted)(1.39)(0.15)(5.19)
Weighted Avg Shares78.02M78.02M79.19M
Weighted Avg Shares (Diluted)78.02M78.02M81.7M

Hinge Health, Inc.

NYSE:HNGE

Intrinsic Alpha fair value

Locked

Current Price

$114.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.